SPECIAL FEATURES

Highlights of This Issue  3197

CCR Translations

3199  The Dark Side of Innate Immunity Fosters Tumor Growth and Offers New Diagnostic
Ennio Carbone
See related article, p. 3304

3202  One Clever Macrophage Checkpoint
Alberto Mantovani and Raffaella Bonecchi
See related article, p. 3289

CCR Drug Updates

3205  FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Review

3210  Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Marta Ochoa de Olza, and Elena Garralda

CLINICAL TRIALS: TARGETED THERAPY

3220  Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

3229  A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children’s Oncology Group Phase I and Pilot Consortium (ADVL0921)
Yael P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Saffran, Herman Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barksas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, and Brenda J. Weigel

CLINICAL TRIALS: IMMUNOTHERAPY

3239  Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600E-mutated Metastatic Melanoma
Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Köppen, Jessie J. Hsu, Ilseul Chang, Ivo Caro, Isabelle Rooney, Grant A. McArthur, and Antoni Ribas

3247  Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

3259  Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

3266  Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging
Yiyu Xu, Ahmad Hosny, Roman Zelenak, Chintan Parmar, Thibaud Coroller, Idalid Franco, Raymond H. Mak, and Hugo J.W.L. Aerts
Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma

Dipika R. Mohan, Antonio Marcondes Lerario, Tobias Else, Bhramar Mukherjee, Madson Q. Almeida, Michelle Vinco, Julilee Rege, Beatriz M. P. Mariani, Maria Claudia N. Zerbini, Berenice B. Mendonca, Ana Claudia Latronico, Suely K. N. Marie, William E. Rainey, Thomas J. Giordano, Maria Candida B. V. Fragoso, and Gary D. Hammer

Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors

Miro Viitala, Reetta Virtakoivu, Sina Tadayon, Jenna Rannikko, Sirpa Jalkanen, and Maija Hollmén

Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma

Meng Duan, Shyamal Goswami, Jie-Yi Shi, Lin-Jie Wu, Xiao-Ying Wang, Jia-Qiang Ma, Zhao Zhang, Yang Shi, Li-Jie Ma, Shu Zhang, Rui-Bin Xi, Ya Cao, Jian Zhou, Jia Fan, Xiao-Ming Zhang, and Qiang Gao

A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis

Zhijun Zhou, Guanggai Xia, Zhen Xiang, Mingyang Liu, Zhewei Wei, Jie Yan, Wei Chen, Jiantao Zhu, Nianjan Awasthi, Xiaotian Sun, Kar-Ming Fung, Yulong He, Min Li, and Changhua Zhang

PDK1 Mediates NOTCH1–Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition

Vaishnavi Sambandam, Mitchell J. Frederick, Li Shen, Pan Tong, Xiayu Rao, Shaohua Peng, Ratnaker Singh, Tuhina Mazumdar, Chenfei Huang, Qiuli Li, Curtis R. Pickering, Jeffery N. Myers, Jing Wang, and Faye M. Johnson

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osmertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Benjamin P. Brown, Yun-Kai Zhang, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfeng Du, Jarrod A. Smith, Jeffrey S. Ross, Vincent A. Miller, Siraj Ali, Lyudmila Buzhernova, Alexa B. Schrock, Jens Meiler, and Christine M. Lovly

Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination

Shelby Lennon, Ayman Oweida, Dallin Milner, Andy V. Phan, Shilpa Bhatia, Benjamin Van Court, Laurel Darragh, Adam C. Mueller, David Raben, Jorge L. Martínez-Torrejón, Todd M. Pitts, Hilary Somerset, Kimberly R. Jordan, Kirk C. Hansen, Jason Williams, Wells A. Messersmith, Richard D. Schulick, Philip Owens, Karyn A. Goodman, and Sana D. Karam

Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas

Hao-Wen Sim, Romina Nejad, Wenjiang Zhang, Farshad Nassiri, Warren Mason, Kenneth D. Aldape, Gelareh Zadeh, and Eric X. Chen

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases

Franziska M. Ippen, Christopher A. Alvarez-Breckenridge, Benjamin M. Kuter, Alexandra L. Fink, Ivanna V. Biltun, Matthew Lstraeves, Tristan Penson, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbi-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, and Priscilla K. Brastianos

Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma

Velina S. Atanasova, Celine Pournerey, Mehdi Farshchian, Michael Lawler, Christian A. Brown IV, Stephen A. Watt, Sheila Wright, Michael Warkala, Christina Guttmann-Gruber, Josefnia Piñón Hofbauer, Ignacija Fuentes, Marco Prisco, Elham Rashidghamati, Cristina Has, Julio C. Salas-Alais, Francis Palisson, Alain Hovnanian, John A. McGrath, Jemima E. Mellerio, Johann W. Bauer, and Andrew P. South

Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors

Jonathan M. Cooper, Amish J. Patel, Zhiguo Chen, Chung-Ping Liao, Kun Chen, Juan Mo, Yong Wang, and Lu Q. Le
Trabectedin inhibits EWS-FLI1 and evicts SWI/SNF from chromatin in a schedule-dependent manner

Combined Aurora Kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck
Jong Woo Lee, Janaki Parameswaran, Teresa Sandoval-Schaefer, Ryung Jin Eoh, Dong-hua Yang, Fang Zhu, Roshan Sharma, Stephen G. Gaffney, Elizabeth B. Perry, Jeffrey P. Townsend, Ilya G. Serebiiskii, Erica A. Golemis, Natalia Issaeva, Wendell G. Yarbrough, Ja Seok Koo, and Barbara Burtiness

PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma
Henry G. Smith, David Mansfield, Victoria Roulstone, Joan N. Kyula-Currie, Martin McLaughlin, Radhika R. Patel, Katharina F. Bergerhoff, James T. Paget, Magnus T. Dillon, Aadir Khan, Alan Melcher, Khin Thway, Kevin J. Harrington, and Andrew J. Hayes

B7-H3 expression in Merkel cell carcinoma—associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density

LETTERS TO THE EDITOR

Anti–CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers—Letter
Roberto Ferrara, Sandrine Susini, and Aurelien Marabelle

Anti–CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers—Response
Anu Sharma, Sumit K. Subudhi, Jorge Blando, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, and Padmanee Sharma

Table of Contents